

# Wissenschaftliche Arbeiten Prof. Dr. med Rainer Küfer

## A. Originalarbeiten

1. **The Dornier Compact: one year experience with a new generation mobile unit lithotripter for the treatment of renal and ureteral calculi**

T Nesslerauer<sup>1</sup>, R Küfer, J Gschwend, R Hautmann Prog Urol. 1999 Dec;9(6):1046-50. PMID: 1065824

2. **Colour Doppler ultrasound in vesicovaginal fistulas**

B G Volkmer<sup>1</sup>, R Kuefer, T Nesslerauer, M Loeffler, H W Gottfried Ultrasound Med Biol 2000 Jun;26(5):771-5. doi: 10.1016/s0301-5629(00)00210-6. PMID: 10942824

3. **New-generation lithotripters for treatment of patients with implantable cardioverter defibrillator: experimental approach and review of literature.**

Küfer R, Thamasett S, Volkmer B, Hautmann RE, Gschwend JE, J Endourol. 2001 Jun;15(5):479-84. doi: 10.1089/089277901750299258. PMID: 11465325 Review.

4. **[Diagnosis of vesico-intestinal fistulas by contrast medium enhanced 3-D ultrasound].**

Volkmer BG, Nesslerauer T, Küfer R, Löffler M, Maier S, Gottfried HW. Ultraschall Med. 2001 Apr;22(2):81-6. doi: 10.1055/s-2001-12862. PMID: 11398505

5. **Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model.**

Kunzi-Rapp K, Genze F, Küfer R, Reich E, Hautmann RE, Gschwend JE. J Urol. 2001 Oct;166(4):1502-7. doi: 10.1016/s0022-5347(05)65820-x. PMID: 11547121

6. **An innovative mobile lithotripter for extracorporeal shock wave lithotripsy and therapy.**

Küfer R, Volkmer B, Nesslerauer T, Schneider P, Hautmann RE, Gschwend JE. Urol Int. 2002;69(1):17-20. doi: 10.1159/000064354. PMID: 12119433

7. **Visualization of urinary stones by 3-D ultrasound with surface rendering.**

Volkmer BG, Nesslerauer T, Kuefer R, Engel O, Kraemer SC, Gottfried HW. Ultrasound Med Biol. 2002 Feb;28(2):143-7. doi: 10.1016/s0301-5629(01)00493-8. PMID: 11937275

8. **alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.**

Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, Dunn RL, Chinnaiyan AM, Rubin MA.

Am J Pathol. 2002 Sep;161(3):841-8.

doi: 10.1016/s0002-9440(10)64244-7. PMID: 12213712 Free PMC article.

**9. Evaluation of disintegration in prevesical ureteral calculi by 3-dimensional endo-ultrasound with surface rendering.**

Volkmer BG, Nesslauer T, Kuefer R, Loeffler M, Kraemer SC, Gottfried HW. J Urol. 2002 Aug;168(2):450-3. PMID: 12131286

**10. High-flow priapism: a combined interventional approach with angiography and colour Doppler.**

Volkmer BG, Nesslauer T, Kuefer R, Kraemer S, Goerich J, Gottfried HW. Ultrasound Med Biol. 2002 Feb;28(2):165-9.

doi: 10.1016/s0301-5629(01)00502-6. PMID: 11937278

**11. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer.**

Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA, Day ML.

Clin Cancer Res. 2003 Dec 15;9(17):6447-52. PMID: 14695147

**12. Association between the clinical presentation and epidemiological features of familial prostate cancer in patients selected for radical prostatectomy.**

Paiss T, Herkommer K, Bock B, Heinz H, Vogel W, Kron M, Kuefer R, Hautmann RE, Gschwend JE.

Eur Urol. 2003 Jun;43(6):615-21.

doi: 10.1016/s0302-2838(03)00146-5. PMID: 12767361

**13. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells.**

Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, Rubin MA, Day ML. J Biol Chem. 2003 Jan 10;278(2):1372-9.

doi: 10.1074/jbc.M208772200. PMID: 12393869 Free article.

**14. High-flow priapism: a combined interventional approach with angiography and colour Doppler.**

Volkmer BG, Nesslauer T, Kuefer R, Kraemer S, Goerich J, Gottfried HW. Ultrasound Med Biol. 2002 Feb;28(2):165-9.

doi: 10.1016/s0301-5629(01)00502-6. PMID: 11937278

**15. Evaluation of disintegration in prevesical ureteral calculi by 3-dimensional endo-ultrasound with surface rendering.**

Volkmer BG, Nesslauer T, Kuefer R, Loeffler M, Kraemer SC, Gottfried HW. J Urol. 2002 Aug;168(2):450-3. PMID: 12131286

**16. Outcome in patients with seminal vesicle invasion after radical cystectomy.**

Volkmer BG, Küfer R, Maier S, Bartsch G Jr, Bach D, Hautmann R, Gschwend JE.

J Urol. 2003 Apr;169(4):1299-302.

doi: 10.1097/01.ju.0000057248.09720.e7.PMID: 1262934

**17. [Necessity and usefulness of bioinformatic methods for microarray data analysis].**

Kestler HA, Küfer R.

Urologe A. 2004 Jun;43(6):669-74.

doi: 10.1007/s00120-004-0577-7. PMID: 15112041 Review. German

**18. Cystectomy and orthotopic ileal neobladder: the impact on female sexuality.**

Volkmer BG, Gschwend JE, Herkommer K, Simon J, Küfer R, Hautmann RE.

J Urol. 2004 Dec;172(6 Pt 1):2353-7. doi:

10.1097/01.ju.0000145190.84531.66. PMID: 15538266

**19. [Tissue microarrays. High-throughput procedures to verify potential biomarkers].**

Kuefer R, Hofer MD, Gschwend JE, Rubin MA.

Urologe A. 2004 Jun;43(6):659-67.

doi: 10.1007/s00120-004-0576-8. PMID: 15107975 Review.

**20. The role of metastasis-associated protein 1 in prostate cancer progression.**

Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE,

Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA.

Cancer Res. 2004 Feb 1;64(3):825-9.

doi: 10.1158/0008-5472.can-03-2755. PMID: 14871807

**21. High-flow priapism: colour-Doppler ultrasound-guided supraselective embolization therapy.**

Bartsch G Jr, Kuefer R, Engel O, Volkmer BG.

World J Urol. 2004 Nov;22(5):368-70.

doi: 10.1007/s00345-004-0426-8. Epub 2004 Oct 14. PMID: 15490181

**22. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.**

Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL,

Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta

KJ, Collins C, Sellers WR, Chinnaiyan AM.

Cancer Res. 2004 Jun 1;64(11):3814-22.

doi: 10.1158/0008-5472.CAN-03-3881. PMID: 1517298

**23. Cleavage of beta-catenin by calpain in prostate and mammary tumor cells.**

Rios-Doria J, Kuefer R, Ethier SP, Day ML.

Cancer Res. 2004 Oct 15;64(20):7237-40.

doi: 10.1158/0008-5472.CAN-04-1048. PMID: 15492240

**24. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up.**

Herkommer K, Kuefer R, Gschwend JE, Hautmann RE, Volkmer BG.  
Eur Urol. 2004 Jan;45(1):36-41.  
doi: 10.1016/j.eururo.2003.08.001. PMID: 14667513

**25. Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients.**

Kuefer R, Volkmer BG, Loeffler M, Shen RL, Kempf L, Merseburger AS, Gschwend JE, Hautmann RE, Sandler HM, Rubin MA.  
Prostate Cancer Prostatic Dis. 2004;7(4):343-9.  
doi: 10.1038/sj.pcan.4500751. PMID: 15356680

**26. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.**

Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE, Gschwend JE.  
Br J Cancer. 2004 Jan 26;90(2):535-41.  
doi: 10.1038/sj.bjc.6601510. PMID: 14735205 Free PMC article.

**27. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.**

Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, Rimm DL.  
Am J Pathol. 2004 Mar;164(3):831-40.  
doi: 10.1016/s0002-9440(10)63171-9. PMID: 14982837 Free PMC article.

**28. Is there a correlation between changes in prostate-specific antigen levels after prostate needle biopsies and histology?**

Volkmer B, Herkommer K, Kuefer R, Nesslauer T, Hautmann RE, Gottfried HW.  
J Urol Urogynäkol 2004; 2: 8-11

**29. Changing diagnostic and therapeutic concepts in high-flow priapism.**

Kuefer R, Bartsch G Jr, Herkommer K, Krämer SC, Kleinschmidt K, Volkmer BG, Kuefer R, et al.  
Int J Impot Res. 2005 Mar-Apr;17(2):109-13.  
doi: 10.1038/sj.ijir.3901257. PMID: 15229624 Review.

**30. Influence of nitrate levels in drinking water on urological malignancies: a community-based cohort study.**

Volkmer BG, Ernst B, Simon J, Kuefer R, Bartsch G Jr, Bach D, Gschwend JE., Volkmer BG, et al.  
BJU Int. 2005 May;95(7):972-6.  
doi: 10.1111/j.1464-410X.2005.05450.x.BJU Int. 2005. PMID: 15839916

**31. Is the prostate cancer screening behaviour of men with familial predisposition predictable?**

Paiss T, Kahn D, Küfer R, Maier C, Vogel W, Gschwend JE, Hautmann RE, Herkommer K.

Urologe A. 2005 Apr;44(4):387-92.

doi: 10.1007/s00120-005-0780-1. PMID: 15726312 Clinical Trial.

**32. Assessment of a fragment of e-cadherin as a serum biomarker with predictive for prostate cancer.**

Kuefer R, Hofer MD, Zorn CS, Engel O, Volkmer BG, Juarez-Brito MA, Eggel M, Gschwend JE, Rubin MA, Day ML, Kuefer R, et al.

Br J Cancer. 2005 Jun 6;92(11):2018-23.

doi: 10.1038/sj.bjc.6602599.Br J Cancer. 2005. PMID: 15870707

**33. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer.**

Merseburger AS, Hennenlotter J, Simon P, Kruck S, Koch E, Horstmann M, Kuehs U, Küfer R, Stenzl A, Kuczyk MA

Anticancer Res. 2005 May-Jun;25(3B):1901-7.

PMID: 16158924

**34. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival.**

Volkmer BG, Kuefer R, Bartsch G Jr, Straub M, de Petriconi R, Gschwend JE, Hautmann RE, Volkmer BG, et al.

Cancer. 2005 Dec 1;104(11):2384-91.

doi: 10.1002/cncr.21475.Cancer. 2005. PMID: 16245327

**35. Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer.**

Bachmann N, Hoegel J, Haeusler J, Kuefer R, Herkommer K, Paiss T, Vogel W, Maier C, Bachmann N, et al.

Prostate. 2005 Nov 1;65(3):252-9.

doi: 10.1002/pros.20296.Prostate. 2005. PMID: 16015586

**36. Innovative concepts in early cancer detection and staging of localized prostate cancer**

Rinnab L, Küfer R, Hautmann RE, Volkmer BG, Straub M, Blumstein NM, Gottfried HW

Urologe A. 2005 Nov;44(11):1262, 1264-6, 1268-70,1272-5.

doi:10.1007/s00120-005-0931-4. PMID: 16247635 Review. German.

**37. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.**

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM, Tomlins SA, et al.

Science. 2005 Oct 28;310(5748):644-8.

doi:10.1126/science 117679.Science. 2005. PMID: 16254181

**38. Prognostic factors in lymph node-positive prostate cancer.**

Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA

Urology. 2006 May;67(5):1016-21.  
doi: 10.1016/j.urology.2005.10.055.Urology. 2006. PMID: 16698361

**39. Defining aggressive prostate cancer using a 12-gene model.**

Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin M A, Bismar TA, et al.  
Neoplasia. 2006 Jan;8(1):59-68.  
doi: 10.1593/neo.05664.Neoplasia. 2006. PMID: 16533427

**40. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.**

Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML, Kuefer R, et al.  
Neoplasia. 2006 Apr;8(4):319-29.  
doi: 10.1593/neo.05682. PMID: 16756724 Free PMC article.

**41. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.**

Bastide C, Kuefer R, Loeffler M, de Petriconi R, Gschwend J, Hautmann R, Bastide C, et al.  
Prostate Cancer Prostatic Dis. 2006;9(3):239-44.  
doi: 10.1038/sj.pcan.4500892. PMID: 16832384

**42. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series.**

Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG, Bartsch GC, et al.  
Eur Urol. 2007 Mar;51(3):690-7; discussion 697-8.  
doi:10.1016/j.eururo.2006.07.009. PMID: 16904815

**43. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.**

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA, Perner S, et al.  
Cancer Res. 2006 Sep 1;66(17):8337-41.  
doi: 10.1158/0008-5472.CAN-06-1482. PMID: 16951139

**44. Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway**

Kuefer R, Autenrieth M, Herkommer K, Blum P, Merseburger A, Hofer M, Rinnab L, Gschwend J, Ringhoffer M, Kuefer R, et al.  
Urologe A. 2006 Mar;45(3):328, 330-5.  
doi: 10.1007/s00120-006-1006-x. PMID: 16465522 Review. German.

**45. Application of tissue microarrays for the diagnosis, prognosis and Therapeutic decision making in renal cell carcinoma**

Merseburger AS, Hennenlotter J, Schilling D, Sievert KD, Küfer R, Kuczyk MA.  
Urologe A. 2006 Mar;45(3):323-4, 326-7.  
doi: 10.1007/s00120-006-1005-y. PMID: 16465523

- 46. Cytogenetic alterations in renal tumors. Applications for comparative genomic hybridization and fluorescence in situ hybridization**  
Mertz KD, Tchinda J, Küfer R, Möller P, Rubin MA, Moch H, Perner S, Mertz KD, et al.  
Urologe A. 2006 Mar;45(3):316-8, 320-2.  
doi: 10.1007/s00120-006-1004-z. PMID: 16465524
- 47. Klippel-Trénaunay syndrome. A rare cause of recurrent macrohematuria: case report**  
Rinnab L, Paiss T, Küfer R, Rinnab L, et al.  
Urologe A. 2006 Jun;45(6):739-41.  
doi: 10.1007/s00120-006-1033-7. PMID: 16598450
- 48. Prospective evaluation of prostate cancer screening in men with a family history of the disease.**  
Paiss T, Herkommer K, Kahn D, Gschwend JE, Küfer R, Maier C, Vogel W, Högel J, Hautmann RE, Paiss T, et al.  
Urologe A. 2006 Aug;45(8):1002-5.  
doi: 10.1007/s00120-006-1056-0. PMID: 16830128
- 49. Neobladder emptying failure in males: incidence, etiology and therapeutic options.**  
Simon J, Bartsch G Jr, Küfer R, Gschwend JE, Volkmer BG, Hautmann RE, Simon J, et al.  
J Urol. 2006 Oct;176(4 Pt 1):1468-72; discussion 1472.  
doi: 10.1016/j.juro.2006.06.048. PMID: 16952662
- 50. Use of transrectal ultrasound-guided biopsy in the diagnosis of pelvic malignancies.**  
Rinnab L, Küfer R, Hautmann RE, Gottfried HW, Rinnab L, et al.  
J Clin Ultrasound. 2006 Nov-Dec;34(9):440-5.  
doi: 10.1002/jcu.20278. PMID: 17109402
- 51. Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer.**  
Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA, Collins C, Paris PL, et al.  
Neoplasia. 2006 Dec;8(12):1083-9.  
doi: 10.1593/neo.06421. PMID: 17217626
- 52. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.**  
Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML, Davis JN, et al.  
Cancer Res. 2006 Dec 15;66(24):11897-906.  
doi: 10.1158/0008-5472.CAN-06-2497. PMID: 17178887
- 53. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.**

Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA, Perner S, et al.  
Hum Pathol. 2007 May;38(5):696-701.  
doi: 10.1016/j.humpath.2006.11.012. PMID: 17320151

**54. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.**

Merseburger AS, Hennenlotter J, Stenzl A, Beger G, Rinnab L, Kuczyk MA, Kuefer R. Merseburger AS, et al.  
Urol Int. 2007;79(1):41-3.  
doi: 10.1159/000102912.PMID: 17627167

**55. Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer.**

Kuefer R, Genze F, Zugmaier W, Hautmann RE, Rinnab L, Gschwend JE, Angelmeier M, Estrada A, Buechele B, Kuefer R, et al.  
Neoplasia. 2007 Mar;9(3):246-53.  
doi: 10.1593/neo.06766. PMID: 17401464 Free PMC article.

**56. Clinical value of transrectal ultrasound in the diagnosis of suspected neoplasia in the small pelvis.**

Rinnab L, Gottfried HW, Schnöller T, Hautmann RE, Kuefer R, Rinnab L, et al.  
Ultraschall Med. 2007 Apr;28(2):195-200.  
doi: 10.1055/s-2007-963021. PMID: 17516275

**57. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.**

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE, Rinnab L, et al.  
BJU Int. 2007 Oct;100(4):786-93.  
doi: 10.1111/j.1464-410X.2007.07083.x. PMID: 17822459

**58. Ureteral stricture after extracorporeal shock wave lithotripsy. Case report and overview of the spectrum of rare side effects of modern ESWL treatment**

Finter F, Rinnab L, Simon J, Volkmer B, Hautmann R, Kuefer R, Finter F, et al.  
Urologe A. 2007 Jul;46(7):769-72.  
doi:10.1007/s00120-007-1334-5. PMID: 17458533 Review. German.

**59. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series.**

Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG, Bartsch GC, et al.  
Eur Urol. 2007 Mar;51(3):690-7; discussion 697-8.  
doi: 10.1016/j.eururo.2006.07.009. PMID: 16904815

**60. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases.**

Banyard J, Bao L, Hofer MD, Zurakowski D, Spivey KA, Feldman AS, Hutchinson LM, Kuefer R, Rubin MA, Zetter BR, Banyard J, et al.



Clin Cancer Res. 2007 May 1;13(9):2634-42.  
doi: 10.1158/1078-0432.CCR-06-2163. PMID: 17473194

**61. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.**

Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE, Day ML, Zorn CS, et al.

Clin Cancer Res. 2007 Apr 1;13(7):2136-43.

doi: 10.1158/1078-0432.CCR-06-2381. PMID: 17404097

**62. TMPRSS2-ETS gene fusion in prostate cancer**

Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M, Perner S, et al.

Urologe A. 2007 Jul;46(7):754-60.

doi: 10.1007/s00120-007-1347-0. PMID: 17458530 Review. German

**63. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer.**

Rinnab L, Blumstein NM, Mottaghy FM, Hautmann RE, Küfer R, Hohl K, Reske SN, Rinnab L, et al.

BJU Int. 2007 Jun;99(6):1421-6.

doi: 10.1111/j.1464-410X.2007.06776.x. PMID: 17355373

**64. Systemic therapy approaches in patients with bone metastases of urogenital malignancies**

Finter F, Mottaghy FM, Kuefer R, Hautmann RE, Rinnab L, Finter F, et al.

Urologe A. 2007 Aug;46(8):904, 906-12.

doi: 10.1007/s00120-007-1521-4. PMID: 17639296 Review. German.

**65. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.**

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE, Rinnab L, et al.

BJU Int. 2007 Oct;100(4):786-93.

doi: 10.1111/j.1464-410X.2007.07083.x. PMID: 17822459

**66. Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia.**

Sträter J, Wiesmüller C, Perner S, Kuefer R, Möller P, Sträter J, et al.

Histopathology. 2008 Feb;52(3):399-402.

doi: 10.1111/j.1365-2559.2007.02923.x. PMID: 18081815

**67. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction.**

Simon J, Kuefer R, Bartsch G Jr, Volkmer BG, Hautmann RE, Gottfried HW, Simon J, et al.

BJU Int. 2008 Aug;102(4):459-62.

doi: 10.1111/j.1464-410X.2008.07560.x. PMID: 18325061

- 68. Terminology of lower urinary tract dysfunction and coding in the ICD-10-GM catalogue**  
Finter F, Petschl S, Küfer R, Simon J, Volkmer BG, Finter F, et al.  
Urologe A. 2008 May;47(5):596-600.  
doi: 10.1007/s00120-008-1672-y. PMID: 18320164
- 69. Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches**  
Rinnab L, Hessenauer A, Schütz SV, Schmid E, Küfer R, Finter F, Hautmann RE, Spindler KD, Cronauer MV, Rinnab L, et al.  
Urologe A. 2008 Mar;47(3):314-25.  
doi: 10.1007/s00120-008-1637-1. PMID: 18273598
- 70. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma.**  
Bachmann N, Haeusler J, Luedeke M, Kuefer R, Perner S, Assum G, Paiss T, Hoegel J, Vogel W, Maier, C. Bachmann N, et al.  
Cancer Genet Cytogenet. 2008 Apr 15;182(2):103-10.  
doi: 10.1016/j.cancergencyto.2008.01.006. PMID: 18406871
- 71. Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?**  
Schilling D, Küfer R, Kruck S, Stenzl A, Kuczyk MA, Merseburger AS, Schilling D, et al.  
Urologe A. 2008 Oct;47(10):1334-8.  
doi: 10.1007/s00120-008-1781-7. PMID: 18566791
- 72. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?**  
Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler KD, Cronauer MV, Rinnab L, et al.  
Neoplasia. 2008 Jun;10(6):624-34.  
doi: 10.1593/neo.08248. PMID: 18516299
- 73. 11C Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer.**  
Rinnab L., Mottaghy F.M., Simon J., Volkmer B.G., de Petriconi R., Hautmann R.E., Wittbrodt M., Egghart G., Moeller P., Blumstein N., Reske S., Kuefer R.  
Urol Int 2008;81(2):191-7.  
doi: 10.1159/000144059. PMID: 18758218
- 74. Diffusion-weighted Imaging (DWI): Potential Alternative to Conventional MRI Sequences (STIR, T1w-SE) and 11C-Choline PET/CT for M-staging Patients with Prostate Carcinoma.**  
Luboldt W., Küfer R., Blumstein N., Toussaint T.L., Kluge A., Seemann M., Luboldt H.J.  
Radiology 2008 Dec;249(3):1017-25.  
doi: 10.1148/radiol.2492080038. PMID: 18849502

**75. Genome Wide Linkage Analysis of TMPRSS2-ERG Fusion in Familial Prostate Cancer.**

Hofer M.D., Kuefer R., Maier C., Herkommer K., Perner S., Demichelis F., Paiss T., Vogel W., Rubin M.A., Hoegel, J.:  
Cancer Research 2009 Jan 15;69(2):640-6.  
doi: 10.1158/0008-5472.CAN-08-2008. PMID: 1914757

**76. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.**

Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, Kuefer R, Rubin MA, Fimmel CJ, Chinnaiyan AM. Varambally S, et al.  
Neoplasia. 2008 Nov;10(11):1285-94.  
doi: 10.1593/neo.08922. PMID: 18953438 Free PMC article.

**77. 11C-Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study.**

Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, Wittbrodt M, Egghart G, Moeller P, Blumstein N, Reske S, Kuefer R, Rinnab L, et al.  
Urol Int. 2008;81(2):191-7.  
doi: 10.1159/000144059. PMID: 18758218

**78. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.**

Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schürmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA; PRACTICAL Consortium, Eeles RA, Kote-Jarai Z, et al.  
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61.  
doi: 10.1158/1055-9965.EPI-08-0317. PMID: 18708398 Free PMC article.

**79. Transvesical malposition of a transobturator aortofemoral bypass**

Finter F, Küfer R, Simon J, Volkmer BG, Finter F, et al.  
Urologe A. 2008 Nov;47(11):1481-2.  
doi: 10.1007/s00120-008-1811-5. 2008. PMID: 18670750

**80. Nosocomial bacteriuria in patients with indwelling catheter after radical retropubic prostatectomy for prostate cancer.**

Bartsch GC, Kuefer R, Braun C, Simon J, Kleinschmidt K, Hautmann RE, Volkmer BG, Bartsch GC, et al.  
Urol Int. 2008;81(4):389-93.  
doi: 10.1159/000167834. PMID: 19077397

**81. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.**

Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM, Steinkamp MP, et al.  
Cancer Res. 2009 May 15;69(10):4434-42.  
doi: 10.1158/0008-5472.CAN-08-3605. PMID: 19366804 Free PMC article.

**82. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.**

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA, Rickman DS, et al.  
Cancer Res. 2009 Apr 1;69(7):2734-8.  
doi: 10.1158/0008-5472.CAN-08-4926. PMID: 19293179 Free PMC article.

**83. Oncological follow up after radical cystectomy for bladder cancer-is there any benefit?**

Volkmer BG, Kuefer R, Bartsch GC Jr, Gust K, Hautmann RE, Volkmer BG, et al.  
J Urol. 2009 Apr;181(4):1587-93; discussion 1593.  
doi: 10.1016/j.juro.2008.11.112. PMID: 19233433

**84. Distinct genomic aberrations associated with ERG rearranged prostate cancer.**

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA, Demichelis F, et al.  
Genes Chromosomes Cancer. 2009 Apr;48(4):366-80.  
doi: 10.1002/gcc.20647. PMID: 19156837

**85. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.**

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J, Hofer MD, et al.  
Cancer Res. 2009 Jan 15;69(2):640-6.  
doi: 10.1158/0008-5472.CAN-08-2008. PMID: 19147579 Free article.

**86. Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth**

Rinnab L, Gust K, Hautmann RE, Küfer R, Rinnab L, et al.  
Urologe A. 2009 May;48(5):516-22.  
doi: 10.1007/s00120-009-1954-z. PMID: 19296069

**87. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.**

Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C, Luedeke M, et al.  
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5.  
doi: 10.1158/1055-9965.EPI-09-0772. PMID: 19861517 Free article.

**88. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?**

Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE, Volkmer BG, et al.

J Urol. 2009 Dec;182(6):2632-7.

doi: 10.1016/j.juro.2009.08.046. PMID: 19836794

**89. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.**

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Arden-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, et al.

Nat Genet. 2009 Oct;41(10):1116-21.

doi: 10.1038/ng.450. Epub 2009 Sep 20. Nat Genet. 2009.

PMID: 19767753 Free PMC article.

**90. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.**

Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M, Gust KM, et al.

Neoplasia. 2009 Sep;11(9):956-63.

doi: 10.1593/neo.09694. PMID: 19724689 Free PMC article.

**91. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.**

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA, Pflueger D, et al.

Neoplasia. 2009 Aug;11(8):804-11.

doi: 10.1593/neo.09572. PMID: 19649210 Free PMC article.

**92. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.**

Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA, Pienta KJ, Robins DM, Steinkamp MP, et al.  
Cancer Res. 2009 May 15;69(10):4434-42.  
doi: 10.1158/0008-5472.CAN-08-3605. PMID: 19366804 Free PMC article.

**93. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.**

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA, Rickman DS, et al.  
Cancer Res. 2009 Apr 1;69(7):2734-8.  
doi: 10.1158/0008-5472.CAN-08-4926. PMID: 19293179 Free PMC article.

**94. Oncological followup after radical cystectomy for bladder cancer-is there any benefit?**

Volkmer BG, Kuefer R, Bartsch GC Jr, Gust K, Hautmann RE, Volkmer BG, et al.  
J Urol. 2009 Apr;181(4):1587-93; discussion 1593.  
doi:10.1016/j.juro.2008.11.112. PMID: 19233433

**95. Distinct genomic aberrations associated with ERG rearranged prostate cancer.**

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA, Demichelis F, et al.  
Genes Chromosomes Cancer. 2009 Apr;48(4):366-80.  
doi: 10.1002/gcc.20647. PMID: 19156837 Free PMC article.

**96. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.**

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J, Hofer MD, et al.  
Cancer Res. 2009 Jan 15;69(2):640-6.  
doi: 10.1158/0008-5472.CAN-08-2008. PMID: 19147579 Free article.

**97. Palliative systemic therapy of castration-resistant prostate cancer: current developments**

Finter F, Rinnab L, Gust K, Kuefer R.  
Urologe A. 2009 Nov;48(11):1295-301.  
doi: 10.1007/s00120-009-2111-4. PMID: 19847385

**98. Current aspects and medication therapy strategies for out-patient uro-oncological therapy**

Rinnab L, Küfer R. Rinnab L, et al.  
Urologe A. 2009 Nov;48(11):1261-2.  
doi: 10.1007/s00120-009-2102-5. PMID: 19844671

**99. Complementary medicine in oncology**

Schnöller T, Küfer R, Eismann T, Rinnab L. Schnöller T, et al.

Urologe A. 2009 Nov;48(11):1302, 1304-7.  
doi: 10.1007/s00120-009-2110-5. PMID: 19841885

**100. Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy.**

Ringhoffer M, Rinnab L, Küfer R, Greiner J, Ringhoffer M, et al.  
Urologe A. 2009 Nov;48(11):1308-17.  
doi: 10.1007/s00120-009-2109-y. PMID: 19806342

**101. Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth**

Rinnab L, Gust K, Hautmann RE, Küfer R, Rinnab L, et al.  
Urologe A. 2009 May;48(5):516-22.  
doi: 10.1007/s00120-009-1954-z. PMID: 19296069

**102. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.**

Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C, Luedeke M, et al.  
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5.  
doi: 10.1158/1055-9965.EPI-09-0772. 2009. PMID: 19861517 Free article.

**103. Rearrangements of the RAF kinase pathway in prostate cancer, gastric Cancer and melanoma.**

Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM, et al.  
Nat Med. 2010 Jul;16(7):793-8.  
doi: 10.1038/nm.2166. PMID: 20526349 Free PMC article.

**104. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor**

Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S, Scheble VJ, et al.

Mod Pathol. 2010 Aug;23(8):1061-7.

doi: 10.1038/modpathol.2010.87. 2010. PMID: 20473283 Free PMC article.

**105. ERG rearrangement metastasis patterns in locally advanced prostate cancer**

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA, Perner S, et al.  
Urology. 2010 Apr;75(4):762-7.

doi: 10.1016/j.urology.2009.10.010. PMID: 20018353

- 106. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma.**  
Kastler S, Honold L, Luedeke M, Kuefer R, Möller P, Hoegel J, Vogel W, Maier C, Assum G, Kastler S, et al.  
Prostate. 2010 May 1;70(6):666-74.  
doi: 10.1002/pros.21100. 2010. PMID: 20017164
- 107. Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours.**  
Azoitei N, Pusapati GV, Kleger A, Möller P, Küfer R, Genze F, Wagner M, van Lint J, Carmeliet P, Adler G, Seufferlein T, Azoitei N, et al.  
Gut. 2010 Oct;59(10):1316-30.  
doi: 10.1136/gut.2009.206813. PMID: 20732914
- 108. Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer.**  
Greiner J, Küfer R, Reske SN, Martin V, Döhner H, Ringhoffer M, Greiner J, et al.  
Case Rep Med. 2010;2010:395720.  
doi: 10.1155/2010/395720. PMID: 20396674
- 109. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer**  
Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F, Perner S, Braun M, et al  
Histopathology. 2011 Jun;58(7):1028-36.  
doi: 10.1111/j.1365-2559.2011.03862.x. PMID: 21707704
- 110. Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.**  
Azoitei N, Kleger A, Schoo N, Thal DR, Brunner C, Pusapati GV, Filatova A, Genze F, Möller P, Acker T, Kuefer R, Van Lint J, Baust H, Adler G, Seufferlein T, Azoitei N, et al.  
Neuro Oncol. 2011 Jul;13(7):710-24.  
doi: 10.1093/neuonc/nor084. PMID: 21727210 Free PMC article.
- 111. Frequent truncating mutations of STAG2 in bladder cancer.**  
Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T, Solomon DA, et al.  
Nat Genet. 2013 Dec;45(12):1428-30.  
doi: 10.1038/ng.2800. PMID: 24121789
- 112. Histopathology reports of findings of prostate needle biopsies. Individual treatment**



Damjanoski I, Müller J, Schnöller TJ, Küfer R, Rinnab L, Damjanoski I, et al.  
Urologe A. 2013 Feb;52(2):226-39.  
doi: 10.1007/s00120-012-3008-1. PMID: 23064867

113. **Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy**  
Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, Shariat SF, Mosquera JM, Rink M, et al.  
Urol Oncol. 2013 Nov;31(8):1716-24.  
doi: 10.1016/j.urolonc.2012.06.011. PMID: 22944196
114. **Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study**  
Mirone V, Arcaniolo D, Rivas D, Bull S, Aquilina JW, Verze P; PAUSE study team, Mirone V, et al.  
Eur Urol. 2014 Apr;65(4):733-9.  
doi: 10.1016/j.eururo.2013.08.018. PMID: 23993257 Free article. Clinical Trial.
115. **Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.**  
Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF.  
Eur J Surg Oncol. 2014 Jan;40(1):121-7.  
doi: 10.1016/j.ejso.2013.08.023. PMID: 24140000
116. **Re: Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder**  
E. Xylinas, E. K. Cha, F. Khani, L. A. Kluth, M. Rieken, B. G. Volkmer, R. Hautmann, R. Kufer, Y.-T. Chen, M. Zerbib, M. A. Rubin, D. S. Scherr, S. F. Shariat and B. D. Robinson  
J Urol 2014 Mar;191(3):830-41.  
doi: 10.1016/j.juro.2013.08.048. PMID: 23994370
117. **Genetic Variants of DICE1/INTS6 in German Prostate Cancer Families with Linkage to 13q14.**  
Böhm M, Maier C, Küfer R, Röpke A, Vogel W, Wieland I, Böhm M, et al.  
Urol Int. 2015;95(4):386-9.  
doi: 10.1159/000366229. PMID: 25660097
118. **Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.**  
Luedeke M, Rinckleb AE, FitzGerald LM, Geybels MS, Schleutker J, Eeles RA, Teixeira MR, Cannon-Albright L, Ostrander EA, Weikert S, Herkommer K, Wahlfors T, Visakorpi T, Leinonen KA, Tammela TLJ, Cooper CS, Kote-Jarai Z, Edwards S, Goh CL, McCarthy F, Parker C, Flohr P, Paulo P, Jerónimo C, Henrique R, Krause H, Wach S, Lieb V, Rau TT, Vogel W, Kuefer R, Hofer MD, Perner S, Rubin MA, Agarwal AM, Easton DF, Al Olama AA, Benlloch S; PRACTICAL consortium, Hoegel J, Stanford JL, Maier C, Luedeke M, et al.

Hum Mol Genet. 2016 Dec 15;25(24):5490-5499. doi: 10.1093/hmg/ddw349.  
PMID: 27798103 Free PMC article.

**119. Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.**

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S, Offermann A, et al.  
Front Med (Lausanne). 2017 Sep 29;4:157.  
doi: 10.3389/fmed.2017.00157. PMID: 29034236 Free PMC article.

**120. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.**

Hupe MC, Philippi C, Roth D, Kumpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A, Hupe MC, et al.  
Front Oncol. 2018 Dec 20;8:623.  
doi: 10.3389/fonc.2018.00623. PMID: 30619757 Free PMC article.

**121. TRIM24 as an independent prognostic biomarker for prostate cancer.**

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S, Offermann A, et al. Urol Oncol. 2019 Sep;37(9):576.e1-576.e10. doi: 10.1016/j.urolonc.2019.05.006.  
PMID: 31178279

**122. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.**

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.  
Int J Cancer. 2020 Jan 15;146(2):577-588.  
doi: 10.1002/ijc.32551. PMID: 3127144

**123. Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center**

Richard E Hautmann<sup>1</sup>, Björn Volkmer<sup>2</sup>, Günther Egghart<sup>3</sup>, Detlef Frohneberg<sup>4</sup>, Hans-Werner Gottfried<sup>5</sup>, Jürgen Gschwend<sup>6</sup>, Robert Hefty<sup>7</sup>, Klaus Kleinschmidt<sup>8</sup>, Rainer Küfer<sup>9</sup>, Kurt Miller<sup>10</sup>, Robert de Petroni<sup>1</sup>, Jörg Simon<sup>11</sup>, Ulrich Wenderoth<sup>7</sup>

J Urol. 2021 Jan;205(1):174-182.  
doi: 10.1097/JU.0000000000001345. Epub 2020 Aug 28. PMID: 32856988

**124. Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker**

Finn Becker<sup>1</sup>, Anne Offermann<sup>2</sup>, Marie C Roesch<sup>3</sup>, Vincent Joerg<sup>1</sup>, Doris Roth<sup>1</sup>, Verena Lubczyk<sup>4</sup>, Rainer Kuefer<sup>5</sup>, Verena Sailer<sup>1</sup>, Jutta Kirfel<sup>1</sup>, Axel S Merseburger<sup>3</sup>, Sven Perner<sup>6</sup>

Urol Oncol. 2022 Aug;40(8):380.e11-380.e18.

doi: 10.1016/j.urolonc.2022.05.019.Epub 2022 Jun 17. PMID: 35725938

## B. Kasuistiken

1. **Splenosis mimicking lymph node metastases of a testicular seminoma.**  
Kuefer R, Volkmer B, Kotzerke J, Hautmann R, Gschwend J.  
British Journal of Urology 2001
2. **Klippel-Trénaunay syndrome. A rare cause of recurrent macrohematuria: case report**  
Rinnab L, Paiss T, Küfer R. Urologe A. 2006 Jun;45(6):739-41.  
doi:10.1007/s00120-006-1033-7. PMID: 16598450
3. **Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer.**  
Greiner J, Küfer R, Reske SN, Martin V, Döhner H, Ringhoffer M.  
Case Rep Med. 2010;2010:395720.  
doi: 10.1155/2010/395720. PMID: 20396674

## C. Eingeladene Beiträge

1. Dornier Compact Delta - Beginn einer neuen Generation der mobilen Lithotripsie. Kuefer R: Kongress-Ausgabe der Deutschen Gesellschaft für Urologie, Medizin und Technik, Thieme 1998; 5
2. Serum Osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. C.L.Eaton et al. The Prostate 59:304-310 (2004)  
Kuefer R, Paiss T. Kommentar in Aktuelle Urologie, Thieme, April 2005; 2:80-81
3. Innovative concepts in early cancer detection and staging of localized prostate cancer  
Rinnab L, Küfer R, Hautmann RE, Volkmer BG, Straub M, Blumstein NM, Gottfried HW.

- Urologe A. 2005 Nov;44(11):1262, 1264-6, 1268-70, 1272-5.  
doi: 10.1007/s00120-005-0931-4. PMID: 16247635
4. Molecular biological elucidation of renal cell carcinoma.  
Kuefer R, Hautmann R: Urologe A. 2006 Mar;45(3):295-6.  
doi: 10.1007/s00120-006-1010-1.PMID: 16482464
  5. Research at the Ulm University in prostate cancer  
Rinnab L, Cronauer M, Spindler D, Hautmann RE, Küfer R.  
Urologe A. 2007 Sep;46(9):1071-7.  
doi: 10.1007/s00120-007-1422-6. PMID: 17628778
  6. History of high-flow priapism. 1960-2005  
Engel O, Bartsch G, Küfer R, Braun C, Hautmann RE, Volkmer BG  
Urologe A. 2006 Mar;45(3):351-5.  
doi: 10.1007/s00120-005-0957-7.PMID: 16307222 German.
  7. Spitzenforschung in der Urologie: Fortschritte in der Identifikation molekularer Marker beim Prostatakarzinom. Küfer R., Perner S., Rubin M. Wissenschaft. 2007: 40
  8. Prostatakarzinom – eine weit verbreitete und kontrovers diskutierte Erkrankung. Hautmann R., Küfer R., Bamberg M.: Der Onkologe. 2007; (13):667-669.
  9. Biomarker beim Prostatakarzinom. Molekulare Ansätze zur Prognoseabschätzung  
  
Perner S., Mertz K.D., Küfer R., Rubin M.A.:  
Der Onkologe. 2007; (13):669-677.
  10. Impact of patient age on biochemical recurrence rates following radical prostatectomy. Küfer R.: J Urol. 2007 Nov;178(5):1937-8; editorial comment.

## **D. Buchbeiträge**

Peter M. Schlag / Michael Bamberg / Dirk Jäger (Hrsg.)  
Interdisziplinäre Entscheidungswege in der Onkologie  
Diagnose- und Therapiealgorithmen mit Erläuterungen  
Kapitel Prostatakarzinom, Rainer Küfer und Richard E. Hautmann  
Deutscher Ärzteverlag 2011  
(<http://www.aerzteverlag.de/buecher/buch.asp?grid=237&id=2462>)

## **E. Betreuung von Nachwuchswissenschaftlern**

### **Diplomarbeiten**

Herr Michael Tänzer

„Konzeption und Realisation einer Datenbank zur patientenbezogenen Erfassung klinischer Parameter des Prostatakarzinoms“ Diplomarbeit; 2006 abgeschlossen

Fachhochschule Ulm - Fakultät Informatik

Studiengang: Medizinische Dokumentation und Informatik

Frau Kristin Wagner

"Durchführung der systematischen Therapie bei Patienten mit Karzinomen an der Urologischen Universitätsklinik Ulm" Bachelorarbeit; 2007 abgeschlossen

Hochschule Ulm - Fakultät Informatik

Studiengang: Medizinische Dokumentation und Informatik

### **Masterarbeit**

Frau Dorothee Pflüger

„Towards Understanding of Prostate Cancer Heterogeneity“

Urologische Universitätsklinik Ulm; Medizinische Fakultät der Universität Ulm; Masterarbeit im Rahmen des Masterstudiengangs Molecular Medicine 10.2008.

### **Dissertationen**

Peter Liske

„Funktionelle Ergebnisse nach Zystektomie und Anlage einer Ileum-Neoblase: Einfluss der Harnleiter-Implantationstechnik“ Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie

Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2005

Anja Hägele

„Komplikationen nach radikaler Zystektomie und Anlage einer Ileum-Neoblase“ Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie

Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2007

Thomas Huckle

„Seltene Harnblasenmalignome“

Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie

Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2007

Herr Marc Peter Schlegel

„Analyse eines Kombinationsbiomarkers mit prädiktivem Wert beim Prostatakarzinom“  
Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie  
Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2008

Frau Ursula Schertl

„Klinischer Stellenwert der Lymphocelenbildung nach pelviner Lymphadenektomie“  
Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie  
Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2008

Frau Andrea Ebert

„Wertigkeit klinischer Scoring-Systeme zur Abschätzung des perioperativen kardiovaskulären Risikos vor Prostataektomie“  
Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie  
Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2009

Frau Isabella Sieber

„Ein Spaltprodukt des E-cadherin als Serumbiomarker beim Prostatakarzinom“  
Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie  
Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2009

Frau Pia Pialozzi

„Over- and Understaging des klinischen T3 Prostatakarzinoms“  
Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie  
Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2009

Herr Marcel Hanisch

„Evaluation der klinisch relevanten Parameter der Prostatastanzbiopsie“  
Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie  
Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2009

Frau Pascale Gilliot

„Stellenwert der Multistanze beim Prostatakarzinom“  
Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie

Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2010

Herr Vedat Altug

„Stellenwert von Butyraten in der Chemoprevention und Chemotherapie des Prostatakarzinom“

Urologische Universitätsklinik Ulm; Abteilung für Urologie und Kinderurologie

Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Ulm 2016

Frau S. Hohensteiner

“TRIM24 as an independent prognostic biomarker for prostate cancer”

Abteilung Pathologie; Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Universität Lübeck 2019